Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...
OncoCyte Corporation: Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Q4 2024 revenue of $1.5 million in pharma services; full year revenue of $1.9 millionGraftAssure RUO assay launched July ...
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript
Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We ...
JD Supra14d
FDA’s Backup LDT Enforcement Method: Specimen Collection Kits
We have written at length about the U.S. Food and Drug Administration’s (FDA’s) actions to promulgate regulations specifying the agency’s authority ...
Idexx's Economic Moat Remains Solid, but Softer Consumer Confidence Could Weigh on Near Term
Idexx's financial health is strong. The firm had historically funded its expansions and acquisitions primarily through its own cash generation and held virtually no long-term debt until 2014. Unlike ...
FMIBlog10d
Global Therapeutic Drug Monitoring Market Set to Surge Beyond, Projected to Reach USD 2,527.9 Million by 2034, Growing at a 7.7% CAGR
The global therapeutic drug monitoring market is poised for significant expansion, with projections indicating a rise from USD 1,203.9 million in 2024 to an impressive USD 2,527.9 million by 2034.